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Abstract
GH3 rat pituitary tumor cells produce GH and prolactin
(PRL), but lack the GHRH receptor (GHRH-R). We
expressed human GHRH-R (hGHRH-R) in GH3 cells
using recombinant adenoviral vectors and studied the
eﬀects of GHRH antagonists. The mRNA expression of
the GHRH-R gene in the cells was demonstrated by
RT-PCR. An exposure of the GH3 cells infected with
hGHRH-R to 1010, 109 and 108 M hGHRH for 1
or 2 h in culture caused a dose-dependent elevation of the
intracellular cAMP concentration and the cAMP eﬄux.
Exposure to hGHRH also elicited dose-dependent
increases in GH and PRL secretion from these cells.
Neither the uninfected nor the antisense hGHRH-R-
infected control cells exhibited cAMP, GH and PRL
responses to GHRH stimulation. GHRH antagonists
JV-1–38 and JV-1–36 applied at 3108 M for 3 h,
together with 109 M GHRH, significantly inhibited the
GHRH-stimulated cAMP eﬄux from the hGHRH-R-
infected cells by 36 and 80% respectively. The more
potent antagonist JV-1–36 also decreased the intracellular
cAMP levels in these cells by 55%. Exposure to JV-1–36
for 1 h nullified the stimulatory eﬀect of GHRH on GH
secretion and significantly inhibited it by 64 and 77% after
2 and 3 h respectively. In a superfusion system, GHRH
at 1010, 109 and 108 M concentrations induced
prompt and dose-related high cAMP responses and smaller
increases in the spontaneous GH secretion of the
hGHRH-R-infected cells. Antagonists JV-1–36 and JV-
1–38 applied at 3108 M for 15 min, together with
109 M GHRH, inhibited the GHRH-stimulated
cAMP response by 59 and 35% respectively. This work
demonstrates that GHRH antagonists can eﬀectively
inhibit the actions of GHRH on the hGHRH-R. Our
results support the view that this class of compounds would
be active clinically.
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Introduction
Various experimental and clinical findings demonstrate the
essential role of growth hormone (GH)-releasing hormone
(GHRH) in the control of secretion of GH and the
regulation of linear growth (Clark & Robinson 1985,
Thorner et al. 1985, Kovacs et al. 1994, 1996, Mayo et al.
1995). Diverse antagonistic analogs of GHRH have been
developed in view of a strong interest in their clinical
applications (Schally & Varga 1999, Schally et al. 2001).
Robberecht et al. (1985) originally showed that an early
and relatively weak GHRH antagonist, [Ac-Tyr1,-
Arg2]hGHRH(1–29)NH2, could inhibit the GHRH-
stimulated adenylate cyclase activity in rat pituitary cells. A
clinical study with this antagonist demonstrated a 60–70%
suppression of the GH hypersecretion in a patient with
acromegaly due to a metastatic GHRH-secreting carci-
noid tumor (Jaﬀe et al. 1997). Subsequently, GHRH
antagonists with greatly increased potency were synthe-
sized in our laboratory (reviewed in Schally & Varga
1999).
GHRH antagonists were thought to be useful for the
treatment of disorders caused by excessive GHRH and/or
GH production, such as acromegaly of hypothalamic
origin, diabetic retinopathy or diabetic nephropathy
(Schally & Varga 1999). A development of progressive
hyperplasia of somatotrophs and adenomatous transfor-
mation under chronic stimulation by human GHRH
(hGHRH) was shown in transgenic mice expressing
hGHRH gene, an animal model of human acromegaly
caused by excessive GHRH secretion (Mayo et al.
1988). Using this model, we demonstrated that GHRH
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antagonists suppressed the release of GH and insulin-like
growth factor-I (IGF-I) (Kovacs et al. 1997a). This sug-
gests that GHRH antagonists could be used clinically in
disorders characterized by excessive GHRH secretion. An
even more important indication for GHRH antagonists
might be the treatment of various cancers. Many recent
studies show that GHRH antagonists can inhibit tumor
growth by several mechanisms. The antitumor eﬀects of
GHRH antagonists were initially thought to be exerted
only indirectly through the inhibition of the release of GH
from the pituitary, which results in the suppression of
hepatic IGF-I production and the reduction in serum
IGF-I levels (Schally & Varga 1999). This indirect mecha-
nism is important for those cancers that depend on IGF-I
as a growth factor (Schally & Varga 1999). A strong
positive association was reported between plasma IGF-I
levels and the risk of prostatic, breast and colorectal cancers
(Chan et al. 1998, Schally et al. 2001). In nude mice
bearing human prostatic, renal or other cancer lines
and osteosarcomas, tumor inhibition induced by GHRH
antagonists was accompanied by a decrease in levels of
serum IGF-I (Pinski et al. 1995, Schally & Varga 1999,
Schally et al. 2001). However, this indirect mechanism
alone could not account for tumor suppression observed in
other cancer models in which GHRH antagonists did not
cause a significant reduction of serum IGF-I levels. The
inhibition of the proliferation of various human cancer cell
lines cultured in vitro and suppression of the production of
IGF-II suggested that the antagonists of GHRH must also
exert some direct eﬀect on tumors. IGF-II, like IGF-I, is
a potent mitogen for many cancers and the suppression of
its production would inhibit tumor growth, but unlike
IGF-I, its synthesis is not controlled by GH (Schally &
Varga 1999). Thus, GHRH antagonists inhibited the
production of IGF-I and IGF-II and the expression of
mRNA for IGF-II in vitro and in vivo in many human
cancer lines, including prostatic, pancreatic and colorectal
cancers (Lamharzi et al. 1998, Szepeshazi et al. 2000a,b).
Still other results demonstrated the expression of mRNA
for GHRH and the presence of biologically active GHRH
in human prostatic and breast cancers, and small-cell lung
carcinoma (SCLC) (Kahan et al. 1999, 2000, Kiaris et al.
1999, Halmos et al. 2002). This suggests that GHRH can
function as an autocrine growth factor (Schally et al. 2001).
In some human cancer models such as H-69 SCLC, the
tumor inhibition induced by GHRH antagonists was not
associated with any significant changes in IGF-I and
IGF-II (Kiaris et al. 1999) and the eﬀects of GHRH
antagonists could be due to the blockade of the stimulatory
action of tumoral autocrine GHRH. A direct action of
GHRH antagonists on tumor growth would have to be
mediated through specific GHRH receptors (GHRH-Rs)
on tumors. The recent demonstration of mRNA for splice
variants of GHRH-R in various human cancers, including
prostatic, pancreatic, renal, breast and ovarian, indicates
that the direct inhibitory eﬀects of GHRH antagonists
might be mediated by these tumoral GHRH-Rs that are
diﬀerent from those found in the pituitary (Halmos et al.
2000, 2002, Rekasi et al. 2000a).
GHRH antagonists JV-1–36 and JV-1–38, developed
recently in our laboratory, exhibit a high binding aﬃnity
to rat pituitary GHRH-R and strongly inhibit the
GHRH-evoked GH release from rat pituitaries in vivo and
in vitro (Varga et al. 1999). The antiproliferative eﬀects of
these antagonists on various human cancer cells expressing
the splice variants of GHRH-R were also demonstrated in
recent studies (Rekasi et al. 2000b, 2001, Schally et al.
2001). However, the activity of these GHRH analogs on
the human pituitary GHRH-R has not been evaluated.
The aim of this study was to demonstrate the eﬃcacy of
antagonists JV-1–36 and JV-1–38 on the human pituitary
receptor. Since human pituitary tissue is not available for
research, we infected the GH3 rat pituitary tumor cell line
that produces GH with adenoviral vector carrying human
GHRH-R (hGHRH-R), as in a previous study (Lee et al.
2001). We then utilized GH3 cells expressing hGHRH-R
to evaluate the eﬀects of GHRH antagonists on the
cAMP, GH and prolactin (PRL) secretion.
Materials and Methods
Peptides
hGHRH(1–29)NH2 (GHRH), and GHRH antagon-
ists [PhAc-Tyr1,-Arg2,Phe(4-Cl)6,Arg9,Abu15,Nle27,-
Arg28,Har29]hGHRH(1–29)NH2 (JV-1–36) and [PhAc-
Tyr1,-Arg2,Phe(4-Cl)6,Har9,Tyr(Me)10,Abu15,Nle27,-
Arg28,Har29]hGHRH(1–29)NH2 (JV-1–38) were syn-
thesized in our laboratory by solid-phase methods and
purified as described (Varga et al. 1999).
Recombinant adenoviral vectors and infection of GH3 cells
GH3 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). The recom-
binant adenoviral vectors carrying the hGHRH-R
(AdGHRH-R) and the antisense hGHRH-R (AdAS)
were described previously (Lee et al. 2001). Transduction
eﬃciency of adenoviral vectors was tested in GH3 cells
using AdCMVGal (Lee et al. 1999). -Galactosidase gene
expression was detected in 95–100% of GH3 cells at 48 h
after infection with 5 plaque forming units/cell of AdC-
MVGal. Therefore, subsequent experiments were per-
formed using the same concentration of AdGHRH-R or
AdAS. Twenty-four hours after infection of GH3 cells
with adenoviral vectors, cells were collected and frozen
in liquid nitrogen until used for the experiments to test
the eﬃcacy of GHRH or GHRH antagonists on the
hGHRH-R.
RNA extraction and RT-PCR for hGHRH-R
Total RNA was extracted from AdAS-infected control,
intact control and AdGHRH-R-infected GH3 cells by
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using Tri-Reagent (Sigma, St Louis, MO, USA) according
to the manufacturer’s instructions. The concentration of
RNA was determined spectrophotometrically at 260 nm.
One microgram of total RNA was reverse transcribed and
amplified using the reagents and protocol of the GeneAmp
RNA PCR Core Kit (Perkin Elmer, Norwalk, CT,
USA). Four microliters of cDNA were amplified by PCR
in a 20 µl mixture containing 1PCR buﬀer, 2 mM
MgCl2, 200 µM of each dNTP, 0·5 µM of each primer
(for hGHRH-R), 0·15 µM of each primer (for -actin),
and 2·5 U/100 µl Amplitaq DNA polymerase. PCR
consisted of 1 cycle at 95 C for 3 min, followed by 30
cycles of 95 C for 30 s, 60 C for 45 s, and 72 C for
1 min for hGHRH-R; or 95 C for 90 s, followed by 30
cycles of 95 C for 15 s and 60 C for 30 s for -actin, and
a final extension at 72 C for 7 min. The primers used
were 5-ATG GGC TGC TGT GCT GGC CAA C-3
(sense) and 5-TAA GGT GGA AAG GGC TCA GAC
C-3 (antisense) for hGHRH-R (Rekasi et al. 2000a); and
the primers for -actin were described previously (Kovacs
et al. 2002). The PCR products were electrophoresed on
1·8% agarose gel and stained with ethidium bromide.
GH3 cell cultures
GH3 cells kept in liquid nitrogen were thawed 24 h before
the experiments. The cells were grown for one passage in
DMEM/Ham’s F-12 containing 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Norcross, GA, USA) and
divided into aliquots of 1·1106 cells. The cell culture
medium was supplemented with 100 U/ml penicillin and
100 µg/ml streptomycin, and the cultures were main-
tained at 37 C in a humidified atmosphere containing
95% air/5% CO2.
In Experiment 1, to evaluate whether the hGHRH-R
transferred to GH3 cells by adenoviral vector mediates
signal transduction and restores hormone secretion in
response to GHRH, we investigated cAMP, GH and PRL
responses of the hGHRH-R-infected and control cells to
GHRH. Before applying GHRH, the cells were treated
with isobutylmethylxanthine for 20 min at 37 C, to block
phosphodiesterase activity and preserve cAMP levels.
Triplicate aliquots of AdGHRH-R-infected, AdAS-
infected control, and intact control GH3 cells were
exposed to 1010, 109 and 108 M GHRH dissolved
in fresh warm medium or to medium alone as control, and
incubation was continued for 120 min at 37 C. After 30,
60 and 120 min, 50 µl samples were taken from the
incubation media, and GH and PRL concentrations were
determined by RIA. cAMP concentration in the incu-
bation media at 120 min was also determined. At the end
of the experiment, the medium was removed and 0·5 ml
ice-cold 0·1 M HCl was added to each aliquot and
harvested. Cell lysates were centrifuged for 10 min at 4 C
to remove protein. The supernatants were neutralized
with an equal volume of 150 mM Tris–HCl buﬀer (pH
8·6) containing 4 mM EDTA, and intracellular cAMP
concentrations were determined.
In Experiment 2, we tested the ability of GHRH
antagonists to inhibit the stimulatory eﬀects of GHRH
mediated by the hGHRH-R. Quadruplicate aliquots of
AdGHRH-R-infected, AdAS-infected control, and intact
control GH3 cells were exposed to 3108 M GHRH
antagonists JV-1–36 or JV-1–38, and to medium as
control. After an incubation for 10 min, 109 M GHRH
or medium (control) was added to the wells, and incu-
bation was continued for 3 h. All peptides were dissolved
in fresh warm medium. At 1, 2 and 3 h of incubation
50 µl samples were taken from the incubation media and
used for GH determination. cAMP concentration in the
incubation media at 3 h was also determined. After
finishing the experiment, cell lysates were obtained as
described in Experiment 1, and cAMP concentrations
were determined by RIA.
Superfused GH3 cell system
To study the time-course of cAMP and GH responses to
GHRH stimulation, experiments were performed in a
dynamic superfusion system. This system was similar to
that described earlier for studying the antagonistic activity
of the GHRH analogs on the dispersed pituitary cells
(Horvath et al. 1995, Kovacs et al. 1996, 1997b). In brief,
cultured cells were harvested, resuspended in 2 ml tissue
culture medium DMEM containing 10% FBS and anti-
biotics, as described for cell cultures, and 2·5–3·0107
cells were transferred into the chambers of the superfusion
apparatus. The cells were allowed to sediment simul-
taneously with 1 ml Sephadex-G-10 equilibrated with
medium and continuously perfused with medium at a flow
rate of 1 ml/3 min. To ensure stable baseline values, the
experiment was started after a recovery period of 2 h.
Three chambers of the superfusion system, containing
AdGHRH-R-infected, AdAS-infected control, and intact
control cells, were used in each experiment. To investigate
the time-course of cAMP and GH responses to GHRH
stimulation mediated by the hGHRH-R, the cells were
subsequently perfused with 1010, 109 and 108 M
GHRH for 30 min at 90 min intervals, and 3 min fractions
of the eﬄuent medium were collected and used for cAMP
and GH determinations. At the beginning and the end of
the experiments, the membrane-depolarizing K+ (25 mM
KCl) was administered for 3 min to check the amount of
releasable hormone in the cells. In other experiments, the
inhibitory eﬀects of GHRH antagonists JV-1–36 and
JV-1–38 on the GHRH-stimulated cAMP production and
GH secretion of the infected cells were tested. In these
tests, AdGHRH-R-infected cells were used in all three
chambers of the superfusion apparatus. After the initial
pulse of K+, 109 M GHRH was applied for 15 min, and
the response was used as reference. Ninety minutes later,
the cells were exposed to GHRH antagonist JV-1–36 or
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JV-1–38 for 9 min, followed by a co-administration of
109 M GHRH and 3108 M antagonist for 15 min.
To check the recovery of the GHRH-R from inhibition,
two additional 109 M GHRH stimuli were applied at
60 min intervals for 15 min. A control chamber, with
AdGHRH-R-infected cells, was perfused with 109 M
GHRH alone at intervals corresponding to the GHRH
exposure of the antagonist-treated cells. cAMP and GH
concentrations in the 3 min fractions were determined by
RIA. cAMP and GH responses to the antagonist treatment
were compared with the first response to GHRH (refer-
ence response) and the corresponding responses to GHRH
in the control chamber.
RIA
For cAMP determinations, a freshly prepared mixture of
triethylamine and acetic anhydride (2:1 v/v) was added to
ice-cold aliquots of the medium fractions and cell lysates
(1:20), and these aliquots were kept frozen at 20 C.
cAMP concentration of the acetylated samples was deter-
mined by double-antibody RIA as described (Csernus
et al. 1999). The antiserum for cAMP was obtained from
US National Institute of Diabetes and Kidney Diseases
(Rockville, MD, USA) (CV-27), while the standard
cAMP and 2-monosuccinyl-cAMP tyrosyl methyl ester
for iodination were purchased from Sigma.
GH concentrations in the superfusion and cell
culture aliquots as well as PRL in the culture media
were measured by double-antibody method using
materials supplied by the US National Hormone and
Pituitary Program, Rockville, MD, USA (rat GH-RP-
2/AFP-3190B, rat GH-I-6/AFP-5676B, anti-rat GH-
RIA-5/AFP411S, rat PRL-RP-3/AFP-4459B, rat
PRL-I-6/AFP-10505B, and anti-rat PRL-S-9/AFP-
131581570). Interassay variation was <15% and intra-assay
variation <10%.
Statistical analysis of data
RIA results from the experiments in cell cultures are
expressed as meansS.E.M. or mean percent of controls
S.E.M. of three or four values in each group. Data were
subjected to one-way ANOVA, followed by a Tukey test.
A P value less then 0·05 was considered significant. The
superfusion data were analyzed with a computer program
developed in our institute (Csernus & Schally 1991). In
brief, the program first separates the fractions containing a
basal level of the secreted material from the response
fraction by using several iterations. The statistical param-
eters of the baseline are determined from the values of the
basal fractions. A fraction is considered as a response if it is
larger or smaller than the 95% confidence limits of the
baseline. Using this program, we analyzed the peaks and
calculated the net integral value of the area under the peak
(the diﬀerence between the total area under the peak and
the area under the baseline), representing the net amount
of cAMP or GH released by the cells in response to
stimuli. The inhibitory activity of GHRH antagonists is
expressed as percent inhibition of the reference response.
When cAMP or GH responses of the cells to subsequent
GHRH stimulations in the control chamber were diﬀer-
ent from the reference response, percent inhibition was
adjusted by the corresponding control response.
Results
RT-RCR analysis of the AdGHRH-R-infected and control
GH3 cells
The mRNA expression of hGHRH-R and -actin in
GH3 cells is shown in Fig. 1. The PCR products were of
the expected size of 144 bp (hGHRH-R) and 542 bp
(-actin). The expression of the hGHRH-R was found
only in GH3 cells infected with AdGHRH-R. Control
cells infected with AdAS and intact control GH3 cells
showed no mRNA expression of the hGHRH-R. PCR
products obtained without transcription or using water as a
template were also negative (Fig. 1).
cAMP, GH and PRL responses to GHRH in
AdGHRH-R-infected GH3 cell cultures
cAMP levels were measured to evaluate whether the
hGHRH-R transferred to GH3 cells by adenoviral vector
mediates signal transduction in response to GHRH. Dose-
dependent increases in cAMP eﬄux and intracellular
cAMP concentration were detected in GH3 cells infected
with AdGHRH-R after exposure to 1010, 109 and
108 M GHRH for 120 min. GH3 control cells infected
with AdAS and intact GH3 cells showed no increases in
cAMP in response to GHRH (Fig. 2a and b).
Figure 1 RT-PCR analysis of expression of mRNA for hGHRH-R
and -actin in GH3 cells. The products were of the expected size
of 144 bp (hGHRH-R) and 542 bp (-actin). Lane M, 100 bp DNA
molecular mass marker; lane 1, AdAS-infected control GH3 cells;
lane 2, intact control GH3 cells; lane 3, AdGHRH-R-infected GH3
cells; lanes 4, 5 and 6, AdAS-infected control, intact control and
AdGHRH-R-infected GH3 cells, without transcription respectively;
lane N, negative control, using water as template.
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To investigate whether the hGHRH-R transferred to
GH3 cells is able to restore hormone secretion, GH and
PRL responses of the cells to GHRH stimulation were
evaluated. A dose-dependent increase in GH and PRL
secretion was found in the AdGHRH-R-infected GH3
cells at 60 and 120 min after the addition of increasing
doses of GHRH (Fig. 3a). AdAS-infected control and
intact control GH3 cells showed no GH or PRL responses
to GHRH stimulation (Fig. 3b and c).
Inhibition of stimulated cAMP production and GH secretion
by GHRH antagonists in AdGHRH-R-infected GH3 cell
cultures
To study the eﬃcacy of GHRH antagonists in competing
with GHRH for the hGHRH-R, GH3 cells infected with
AdGHRH-R were exposed to GHRH alone or GHRH
together with a GHRH antagonist (Fig. 4a–c). GHRH
at 109 M induced a 15·7-fold increase (P<0·001) in
the cAMP eﬄux from the GH3 cells infected with
AdGHRH-R after 3 h, compared with untreated control
cells. Antagonists JV-1–36 and JV-1–38, applied at
3108 M concentration, inhibited the GHRH-
stimulated cAMP eﬄux from these cells by 80·4%
(P<0·001) and 36·3% (P<0·01) respectively (Fig. 4a). The
intracellular cAMP levels in the hGHRH-R-infected
cells were elevated by 103% (P<0·001) after the expo-
sure to GHRH for 3 h. The more potent antagonist,
JV-1–36, also inhibited the GHRH-elicited increase
in the intracellular cAMP levels by 55% (P<0·01)
(Fig. 4b).
Treatment of the AdGHRH-R-infected cells with
109 M GHRH alone for 1, 2 and 3 h increased the GH
secretion by 72·8, 225 and 304% respectively (P<0·001
compared with untreated controls) (Fig. 4c). The more
potent antagonist JV-1–36 abolished the stimulatory eﬀect
of GHRH on GH secretion at 1 h (P<0·001), and
significantly inhibited it by 63·8 and 73·6% (both
P<0·001) at 2 and 3 h respectively. Antagonist JV-1–38
was found to be less potent; it suppressed the GHRH-
stimulated GH secretion by 20·0% at 1 h (P<0·01) and by
44·9% at 2 h (P<0·01), and showed no significant eﬀect at
3 h (Fig. 4c).
cAMP and GH responses to GHRH in a superfusion system
To study the time-course of cAMP and GH responses
to GHRH stimulation, GH3 cells infected with
AdGHRH-R were perfused with increasing doses of
GHRH, and the amounts of cAMP and GH released from
the cells were measured in 3 min fractions (Fig. 5a and b).
A perfusion of the AdGHRH-R-infected cells with
1010, 109 and 108 M GHRH for 30 min at 90 min
intervals induced prompt and dose-dependent increases in
the cAMP eﬄux amounting to 18·3, 51·6 and 110 ng
respectively. The membrane depolarizing K+ (25 mM
KCl) did not induce cAMP release (Fig. 5a). Control GH3
cells infected with AdAS and intact control GH3 cells
showed no cAMP response to GHRH stimulation (data
not shown).
The basal GH secretion of GH3 cells infected with
AdGHRH-R was 7·990·11 ng/3 min (Fig. 5b). The
exposure of these cells to 1010, 109 and 108 M
GHRH for 30 min at 90 min intervals induced net
increases in the basal GH secretion of 41·3, 85·1 and
97·7 ng respectively. These values represent only 52, 106
and 122% increases over the basal GH secretion (79·9 ng/
30 min). The highest dose of GHRH (108 M) induced
a somewhat lower GH peak, but more protracted GH
release than the 109 M dose (Fig. 5b). The perfusion of
the cells with the membrane depolarizing K+ for 3 min
evoked a release of 24·4 ng GH at the beginning and
9·30 ng at the end of the experiment, indicating that the
GH content of the cells was depleted by about 60% at the
end of the experiment (Fig. 5b). GH3 cells infected with
AdAS and intact GH3 cells showed no GH response to
GHRH stimulation (data not shown). However, a basal
GH secretion at the rate of 21·6 ng/3 min and 14·2 ng/
3 min respectively was seen in these cells.
Inhibition of stimulated cAMP and GH release by GHRH
antagonists in a superfusion system
The inhibitory eﬀect of GHRH antagonists on the
hGHRH-R was also evaluated in the superfusion system.
Figure 2 GHRH-stimulated cAMP production in GH3 cell cultures:
cAMP efflux (a) and intracellular cAMP accumulation (b) of
AdGHRH-R-infected, AdAS-infected control and intact control
GH3 cells after stimulation with increasing doses of GHRH for
120 min. MeansS.E.M. of three determinations.
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AdGHRH-R-infected cells were perfused with GHRH
alone (control chamber), or simultaneously with GHRH
and GHRH antagonist, and the cAMP and GH responses
of the cells were measured (Fig. 6a–c). A repeated
perfusion of the AdGHRH-R-infected cells with 109 M
GHRH for 15 min caused prompt and high increases
(18·21·32 ng net release) in the cAMP production. The
perfusion of the cells with KCl did not produce significant
changes in the cAMP eﬄux (Fig. 6a). An exposure of
cells to 3108 M GHRH antagonist JV-1–36 for
9 min, followed by 15 min superfusion with JV-1–36
(3108 M) together with GHRH (109 M), sup-
pressed the cAMP response of the cells by 59%, compared
with the first (reference) response to 109 M GHRH
(Fig. 6b). Following the treatment with JV-1–36, cAMP
responses to GHRH were gradually restored, but a
30% and a 24% inhibition could still be detected after 60
and 120 min respectively, compared with the reference
response (Fig. 6b), adjusted by the corresponding control
response (Fig. 6a). The antagonist JV-1–38 was found to
be somewhat weaker than JV-1–36 in inhibiting GHRH
at 0 min. This antagonist, at 3108 M concentration,
decreased the GHRH-induced cAMP eﬄux of the
AdGHRH-R-infected cells by 33–37% at 0, 60 and
120 min after administration (not shown). Either antagon-
ist, applied for 9 min prior to GHRH, induced a small
increase of the cAMP eﬄux (less than 15% compared with
the reference response; see Fig. 6b for JV-1–36).
A moderate, but significant stimulation of GH secretion
by repeated perfusion with 109 M GHRH was observed
in the control chamber containing AdGHRH-R-infected
cells (not shown). An exposure of the cells to GHRH
antagonists JV-1–36 (Fig. 6c) or JV-1–38 (not shown),
followed by the superfusion with the antagonist together
with GHRH, decreased the GH response by 37–39%,
compared with the reference response adjusted by the
corresponding control response. No significant inhibition
of stimulated GH secretion was seen at 60 or 120 min after
exposure to either antagonist. GH responses to K+ were
decreased by 45–50% at the end of the experiment,
compared with the initial response, in both the antagonist-
exposed and the control chamber (Fig. 6c).
Figure 3 GHRH-stimulated GH and PRL responses in GH3 cell cultures. GH and PRL release from AdGHRH-R-infected (a),
AdAS-infected control (b) and intact control GH3 cells (c) after stimulation with increasing doses of GHRH for 60 and 120 min.
MeansS.E.M. of three determinations.
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Discussion
The GHRH-R, a G-protein coupled receptor, mediates
the action of GHRH on pituitary somatotrophs. The
binding of GHRH to pituitary cells causes the coupling
of the GHRH-R to Gs, resulting in the activation of
adenylate cyclase. In accord with the view that cAMP is an
important second messenger for GHRH signaling, both
GHRH and cAMP increase pituitary GH gene expression
and stimulate the secretion of GH and the proliferation of
somatotroph cells in the pituitary (Mayo 1992). The
hGHRH-R gene is highly homologous to its rat counter-
part, encoding a protein that is 82% identical with the rat
GHRH-R protein (Mayo 1992). To study the eﬃcacy of
our new GHRH antagonists on the hGHRH-R, we
utilized the approach previously developed by Lee et al.
(2001) and based on the transfer of the hGHRH-R gene
to rat pituitary GH3 cells with adenoviral vectors (Wivel
et al. 1999). Using the recombinant adenoviral system, a
functional hGHRH-R can be expressed in rat pituitary
GH3 cells (Lee et al. 2001). The infection with the
AdGHRH-R results in a high mRNA expression of the
hGHRH-R gene and the receptor protein, and restores
the responsiveness to GHRH (Lee et al. 2001). The
present study confirms and extends previous findings by
Lee et al. (2001) by demonstrating that GHRH can
dose-dependently stimulate cAMP production and GH
secretion of the AdGHRH-R-infected cells.
The results obtained from superfusion experiments
revealed some diﬀerences in the behavior of GH3 cell
line, as compared with the normal pituitary somatotrophs
(Horvath et al. 1995). Both the control GH3 cells and
those expressing GHRH-R showed an elevated level of
constitutive GH secretion, but the high cAMP response of
the AdGHRH-R-infected cells to GHRH stimulation
was not accompanied by a comparably high GH response.
Figure 4 Inhibition of cAMP and GH responses to GHRH by
GHRH antagonists in GH3 cell cultures. cAMP efflux (a),
intracellular cAMP level (b) and GH secretion (c) of
AdGHRH-R-infected GH3 cells after incubation with 109 M
GHRH alone or GHRH together with 3108 M GHRH
antagonist JV-1–36 or JV-1–38 for 1, 2 and 3 h. ++P<0·001 vs
untreated controls, **P<0·001 vs GHRH, *P<0·01 vs GHRH.
MeansS.E.M. of four determinations.
Figure 5 cAMP and GH responses to GHRH of the
AdGHRH-R-infected GH3 cells in the superfusion system. cAMP
efflux (a) and GH secretion (b) induced by repeated
administration of GHRH (G) at increasing doses for 30 min at
90 min intervals (horizontal bars). Vertical bars indicate 3 min
perfusion with 25 mM KCl (K), before and after GHRH
stimulations.
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Although a prompt release of both cAMP and GH was
observed in response to GHRH, indicating that the
GH-releasing machinery is working properly in the cells,
GH responses were significantly lower than those of
cAMP, and GH was depleted in the cells after stimulation
with increasing doses of GHRH. Our results are in
agreement with the observations that GH3 cells continu-
ously release synthesized GH and PRL, without storing
them in large amounts (Bancroft et al. 1969, Stachura
1982). Therefore, large intracellular pools of GH are not
available for acute exocytosis during the stimulation with
GHRH. However, the basal expression of the transcrip-
tion factor Pit-1, which regulates the gene expression of
GH and PRL, and is also important for cell proliferation
in neoplastic pituitary cells, is relatively high in GH3
cell line, in the absence of GHRH stimulation (Zhang
et al. 1993, Ying et al. 1999). This may explain the
spontaneously high basal GH secretion of GH3 cells.
The inhibitory eﬀects of GHRH antagonists on the rat
and mouse pituitary GHRH-R and human tumoral
GHRH-R have been demonstrated in several studies
(Kovacs et al. 1996, 1997a, 1997b, Schally & Varga 1999,
Varga et al. 1999, Schally et al. 2001). After the design and
synthesis, our GHRH antagonists are characterized on the
basis of in vitro and in vivo endocrine assays on rat pituitaries
and oncological tests. These oncological tests carried out in
human cancer lines xenografted into nude mice or in vitro
revealed that some of the eﬀects of the GHRH antagonists
must be exerted directly on tumors. Nevertheless, a series
of attempts in our laboratory failed to detect the pituitary
form of GHRH-R in human cancer models (Schally &
Varga 1999). Subsequent work revealed that specimens of
some primary human tumors, such as prostate and lung
cancers, and various human cancer cell lines expressed the
mRNAs corresponding to four truncated splice variants of
GHRH-R, denoted SV1 to SV4, whereas the full-length
pituitary receptor form was not expressed (Halmos et al.
2000, 2002). SV1 appears to be the major isoform of
GHRH-R expressed in neoplastic tissues, which may
mediate the antiproliferative eﬀect of GHRH antagonists
(Halmos et al. 2000, 2002, Rekasi et al. 2000a). Although
the tumoral GHRH-R appears to be diﬀerent from those
in the pituitary, the tumor inhibition induced by GHRH
antagonists is nevertheless exerted in part by an indirect
mechanism based on suppression of GH release from the
pituitary and the reduction in hepatic production of IGF-I
(Schally et al. 2001). Because endocrine tests were carried
out using rat pituitaries and GHRH antagonists were
developed for clinical applications, it was important to
establish the eﬃcacy of these antagonists on the human
pituitary receptor as the rat pituitary GHRH-R shows an
18% diﬀerence in the amino acid sequence as compared
with its human counterpart (Mayo 1992). Our findings
from both cell culture and superfusion experiments show
that GHRH antagonists JV-1–36 and JV-1–38 eﬀectively
inhibit the actions of GHRH on the hGHRH-R. The
more potent antagonist JV-1–36 totally prevented the
stimulatory eﬀect of hGHRH on GH secretion after 1 h
and suppressed the stimulated GH secretion by 64–74%
after 2–3 h in GH3 cells expressing the hGHRH-R. The
other antagonist, JV-1–38, also significantly inhibited the
stimulatory action of GHRH, but was less potent. A small
Figure 6 GHRH-stimulated cAMP efflux from the
AdGHRH-R-infected GH3 cells in the superfusion system, and
inhibition of the stimulated cAMP and GH release by GHRH
antagonist JV-1–36. (a) cAMP efflux was induced by repeated
administration of 109 M GHRH (G) for 15 min (horizontal bars)
in the control chamber. Vertical bars indicate 3 min perfusion with
25 mM KCl (K), before and after GHRH stimulation. (b) cAMP
efflux and (c) GH release in response to 109 M GHRH (G)
applied for 15 min before, during and after administration of
3108 M GHRH antagonist JV-1–36 (A). The cells were
perfused with JV-1–36 (A) for 9 min (short horizontal bar) followed
by a co-perfusion with JV-1–36 and GHRH (A+G) for 15 min
(thick horizontal bar).
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intrinsic agonistic activity of JV-1–36 and JV-1–38 was
observed in the superfusion, but not in the tissue cultures.
In addition, the short-term inhibitory eﬀects of these
antagonists in the superfusion system were found to be
somewhat weaker than their long-term actions in the GH3
cell cultures. These findings can be explained by the
diﬀerent sensitivity of the two test systems to GHRH
peptides. Because in the superfusion experiments we used
a number of hGHRH-R-infected GH3 cells 25 times
greater than for the cell cultures, the former system was
more sensitive than the latter and it could reveal a weak
intrinsic activity of the GHRH antagonists. The suppres-
sion of GHRH-stimulated GH secretion by these antag-
onists was accompanied by a parallel suppression of cAMP
production, indicating that both eﬀects are mediated
by the hGHRH-R. Thus our GHRH antagonists are
active not only on rat and mouse pituitary GHRH-Rs,
and in 3T3 fibroblasts transfected with SV1 variant of
human tumoral GHRH-R (Kiaris et al. 2002), but also on
human pituitary GHRH-R expressed in GH3 cells, as
demonstrated in the present study.
The inhibitory activities of JV-1–36 and JV-1–38
observed in GH3 cells expressing the hGHRH-R corre-
spond to those found in previous work on normal rat
pituitary cells expressing the rat GHRH-R (Varga et al.
1999). In that study, JV-1–36 used at the same dose as in
the present work showed a high and protracted antagon-
istic activity in vivo and in vitro, and its inhibitory eﬀect
on the stimulated GH secretion also exceeded that of
JV-1–38. Thus GHRH antagonists JV-1–36 and JV-1–38
exhibit a similar spectrum of activity on the hGHRH-R
and the rat GHRH-R. Our previous study in rats also
revealed that antagonist JV-1–36 is about 70 times more
potent and longer acting than the GHRH antagon-
ist [Ac-Tyr1, -Arg2]hGHRH(1–29)NH2 (Varga et al.
1999).
In conclusion, this study reports dose-dependent stimu-
latory eﬀects of GHRH on the production and extra-
cellular release of cAMP, as well as on the secretion of GH
and PRL, in rat pituitary GH3 cells subjected to
hGHRH-R gene transfer by adenoviral vector. Our work
also demonstrates for the first time the ability of GHRH
antagonists JV-1–36 and JV-1–38 to inhibit the action of
GHRH on the hGHRH-R. An inhibition by GHRH
antagonist JV-1–36 of the hGHRH-R-mediated eﬀects of
hGHRH indicates that this class of compounds might be
useful in a clinical setting for the treatment of tumors that
are influenced by circulating IGF-I levels.
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